Tag: carcinoid treatments
![ebrahim s delpassand md facnm](https://www.carcinoid.org/wp-content/uploads/2010/08/ebrahim-s-delpassand-md-facnm.jpg)
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
August 24, 2010
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORE![michael j demeure md1](https://www.carcinoid.org/wp-content/uploads/2010/03/michael-j-demeure-md1.jpg)
Carcinoid Cancer Foundation Presents Symposium on Cutting-Edge Treatment
March 23, 2010
Determining Molecular Signature: A Guide for Targeted Therapy of Neuroendocrine Tumors
Imagine a treatment created just for you as a carcinoid or other neuroendocrine tumor patient based upon a personalized genomic analysis. This is the cutting-edge…
READ MORE![laurie todd photo](https://www.carcinoid.org/wp-content/uploads/2010/02/laurie-todd-photo.jpg)
New Message for Carcinoid Patients from “The Insurance Warrior”
February 28, 2010
Laurie Todd, “The Insurance Warrior,” has a special message for the carcinoid community.
The Carcinoid Cancer Foundation is delighted to partner with Laurie to bring you cutting-edge information about how to fight your insurance… READ MORE